DapaSmartM 10/1000: Advanced Type 2 Diabetes Management
DapaSmartM 10/1000 is a combination tablet containing Dapagliflozin 10mg and Metformin 1000mg, formulated for effective blood sugar control in adults with type 2 diabetes. Designed for patients whose blood glucose levels are not sufficiently controlled by diet and exercise alone, this medication supports long-term health and helps prevent diabetes-related complications.
What is DapaSmartM 10/1000?
DapaSmartM 10/1000 combines the benefits of an SGLT2 inhibitor (Dapagliflozin) and a biguanide (Metformin) to efficiently lower blood sugar. Dapagliflozin promotes urinary glucose excretion, while Metformin reduces hepatic glucose production and enhances insulin sensitivity. This dual mechanism supports stable blood glucose levels, helps with weight management, and can improve blood pressure control.
Main Benefits
- Helps regulate blood glucose in adults with type 2 diabetes
- Improves both fasting and postprandial blood sugar levels
- Decreases HbA1c levels
- Supports weight loss and healthy blood pressure maintenance
- Reduces risk of complications like kidney and cardiovascular diseases
How to Take DapaSmartM 10/1000
Take this medication exactly as prescribed, typically once or twice daily with meals to minimize gastrointestinal discomfort. Swallow the tablet whole with water without chewing or crushing. Consistent use along with diet and exercise enhances results.
Possible Side Effects
- Hypoglycemia, especially if combined with other diabetes drugs
- Frequent urination
- Genital or urinary tract infections
- Nausea and stomach discomfort
- Rare but serious: ketoacidosis, dehydration
If you experience excessive thirst, trouble breathing, abdominal pain, or confusion, seek medical help immediately.
DapaSmartM 10/1000
- Dapagliflozin and Metformin combination
- Type 2 diabetes treatment
- Blood sugar control medication
- Effective diabetes tablet
- Benefits and side effects of diabetes medications
- Medication supporting weight management



Reviews
There are no reviews yet.